0001209191-15-052575.txt : 20150611 0001209191-15-052575.hdr.sgml : 20150611 20150611215631 ACCESSION NUMBER: 0001209191-15-052575 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20150611 FILED AS OF DATE: 20150611 DATE AS OF CHANGE: 20150611 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Invuity, Inc. CENTRAL INDEX KEY: 0001393020 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: CA BUSINESS ADDRESS: STREET 1: 444 DE HARO STREET CITY: San Francisco STATE: CA ZIP: 94107 BUSINESS PHONE: 415-655-2100 MAIL ADDRESS: STREET 1: 444 DE HARO STREET CITY: San Francisco STATE: CA ZIP: 94107 FORMER COMPANY: FORMER CONFORMED NAME: Spotlight Surgical Inc DATE OF NAME CHANGE: 20070313 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Roberts Eric W CENTRAL INDEX KEY: 0001576244 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37417 FILM NUMBER: 15927310 MAIL ADDRESS: STREET 1: VALENCE LIFE SCIENCES LLC STREET 2: 500 PARK AVENUE 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2015-06-11 0 0001393020 Invuity, Inc. IVTY 0001576244 Roberts Eric W INVUITY, INC. 444 DE HARO STREET SAN FRANCISCO CA 94107 1 0 0 0 Series D Preferred Stock Common Stock 31728 D Series D Preferred Stock Common Stock 286969 I See footnote Series E Preferred Stock Common Stock 11584 D Series E Preferred Stock Common Stock 38065 I See footnote Director Stock Option (right to buy) 11.10 2025-04-16 Common Stock 10810 D 31,452 outstanding shares of Series D Preferred Stock shall automatically convert into 31,728 shares of Common Stock, on a 1.008821799-for-one basis, immediately prior to the closing of the Issuer's initial public offering of common stock and has no expiration date. 284,460 outstanding shares of Series D Preferred Stock shall automatically convert into 286,969 shares of Common Stock, on a 1.008821799-for-one basis, immediately prior to the closing of the Issuer's initial public offering of common stock and has no expiration date. The shares are held by Valence CDK SPV, L.P. ("Valence CDK"). Valence Life Sciences GP II, LLC ("Valence") is the General Partner of Valence CDK. The Reporting Person is a Managing Member of Valence and disclaims beneficial ownership of the shares held by Valence CDK, except to the extent of his pecuniary interest therein. 11,273 outstanding shares of Series E Preferred Stock shall automatically convert into 11,584 shares of Common Stock, on a 1.027662672-for-one basis, immediately prior to the closing of the Issuer's initial public offering of common stock and has no expiration date. 38,065 outstanding shares of Series E Preferred Stock shall automatically convert into 39,117 shares of Common Stock, on a 1.027662672-for-one basis, immediately prior to the closing of the Issuer's initial public offering of common stock and has no expiration date. The option is subject to an early exercise provision and is immediately exercisable. 50% of the shares subject to the option were fully vested as of the grant of such option. One twenty-fourth of the remaining 50% of the shares subject to the option vested on March 13, 2015 and one twenty-fourth of the remaining 50% of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Exhibit 24 - Power of Attorney /s/ Nancy Hargreaves, by power of attorney 2015-06-11 EX-24 2 attachment1.htm EX-24 DOCUMENT

             LIMITED POWER OF ATTORNEY - SECURITIES LAW COMPLIANCE

        The undersigned, as a Section 16 reporting person of Invuity, Inc. (the
"Company"), hereby constitutes and appoints Brett Robertson, Michael Gandy, and
Nancy Hargreaves the undersigned's true and lawful attorneys-in-fact, to:

        1.      Complete and execute Forms 3, 4 and 5 and other forms and all
amendments thereto as such attorneys-in-fact shall in their discretion determine
to be required or advisable pursuant to Section 16 of the Securities Exchange
Act of 1934, as amended, and the rules and regulations promulgated thereunder,
or any successor laws and regulations, as a consequence of the undersigned's
ownership, acquisition or disposition of securities of the Company; and

        2.      Do all acts necessary in order to file such forms with the
Securities and Exchange Commission, any securities exchange or national
association, the Company and such other person or agency as the
attorneys-in-fact shall deem appropriate.

        The undersigned hereby ratifies and confirms all that said
attorneys-in-fact and agent shall do or cause to be done by virtue hereof. The
undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, is not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934, as amended.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 1st day of May, 2015.

                                        Signature:    /s/ Eric W. Roberts
                                                   -----------------------------

                                        Print Name:   Eric W. Roberts
                                                    ----------------------------